Do Neurofibromas Grow Back After Surgical Removal?
At a Glance
Cutaneous neurofibromas typically do not grow back in the exact spot if fully removed, though new ones may form nearby. Plexiform neurofibromas intertwine with nerves, making complete removal difficult and regrowth highly likely. MEK inhibitors offer a medical alternative for inoperable tumors.
In this answer
3 sections
The short answer is that it depends on the type of neurofibroma. A common myth in the NF1 community is that surgery “angers” tumors and causes them to grow back worse. However, if a cutaneous neurofibroma (the small bumps on the skin) is completely and cleanly removed, it usually does not grow back in that exact spot [1][2]. On the other hand, plexiform neurofibromas—which grow deeply along and inside nerve networks—are much more difficult to remove completely and have a high rate of regrowth [3][4].
Understanding the difference in how these two types of tumors respond to removal can help you make informed decisions about your care.
Cutaneous Neurofibromas
Cutaneous neurofibromas develop on or just under the surface of the skin. Because they are typically localized and less entangled with critical structures, they can often be removed entirely.
Research shows that when these skin tumors are fully excised, most patients do not experience regrowth in the specific area where the surgery was performed [1][2].
So why does it sometimes seem like they grow back? Because NF1 is an underlying genetic condition, your body continues to have the potential to grow new neurofibromas. It is common for a brand-new tumor to develop in the skin immediately adjacent to a surgical scar [1]. This is not the original tumor growing back “worse,” but rather a new tumor forming nearby.
Removal Methods and Scarring
When treating cutaneous tumors, a dermatologist or plastic surgeon might use standard surgical excision, CO2 lasers, or electrodesiccation (using an electric current to destroy the tissue). While these methods are effective for getting rid of the tumor, they do carry a risk of scarring or skin pigment changes [5][6]. For many patients, the decision to remove a skin bump involves weighing the bother of the tumor against the appearance of a potential scar.
Currently, there are no FDA-approved medical treatments (like pills or creams) to shrink cutaneous neurofibromas. While MEK inhibitors (discussed below) are used for deep tumors, clinical trials have shown they do not significantly shrink cutaneous neurofibromas and can actually cause bothersome acne-like skin rashes [7][8].
Plexiform Neurofibromas
Plexiform neurofibromas behave very differently. Instead of forming a distinct, self-contained lump, these tumors grow diffusely along the length of a nerve and its branches, often infiltrating the surrounding healthy nerve tissue. Managing them typically requires a specialized surgical oncologist or neurosurgeon.
Because of this complex, intertwined growth, achieving a gross total resection (complete removal) is often impossible without causing severe nerve damage, loss of function, or substantial bleeding [3][9][10].
When a surgeon cannot safely remove the entire tumor, they perform a subtotal resection (partial removal). The tumor tissue left behind will continue to grow, which is why recurrence rates for plexiform neurofibromas are so high [11]. Even when a tumor appears to be completely removed to the naked eye, microscopic residual tissue can lead to regrowth over time [3][12]. Due to this, surgically managing plexiform neurofibromas can sometimes require multiple operations over a patient’s lifetime [4][13].
Medical Alternatives to Surgery
Because plexiform neurofibromas are difficult to remove and likely to regrow, surgery is no longer the only option. MEK inhibitors, a type of targeted therapy drug, have become an important alternative. For example, the drug selumetinib is FDA-approved specifically for pediatric patients (2 years and older) with symptomatic, inoperable plexiform neurofibromas, and has been shown to successfully shrink or halt the growth of these complex tumors [14][15].
For adult patients, access to MEK inhibitors may involve off-label use or enrolling in clinical trials, as broad FDA approval for adults is still evolving [16]. It is also important to note that these medications are not risk-free alternatives to surgery; they come with their own side effects, requiring regular monitoring for dermatologic rashes, gastrointestinal issues, and cardiac changes [14].
If you are considering surgery for any type of neurofibroma, it is crucial to consult with an NF specialist who can accurately identify the tumor type, discuss the realistic chances of regrowth, and weigh all available treatments.
Common questions in this guide
Do cutaneous neurofibromas grow back after surgical removal?
Why is it so hard to completely remove a plexiform neurofibroma?
Will I have a scar if I have my skin neurofibromas removed?
Am I a candidate for medical management instead of surgery for my neurofibroma?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Am I a candidate for medical management (like a MEK inhibitor) instead of surgery for my tumor?
- 2.If you remove my plexiform neurofibroma, are we aiming for a gross total or subtotal resection?
- 3.What is the specific risk to my nerve function or mobility if this tumor is removed?
- 4.If I have multiple cutaneous neurofibromas removed at once using laser or electrodesiccation, what should I realistically expect regarding scarring?
- 5.If this tumor cannot be completely removed, what is our plan for monitoring it for regrowth or changes?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (16)
- 1
Raman difference spectroscopy and U-Net convolutional neural network for molecular analysis of cutaneous neurofibroma.
Matthies L, Amir-Kabirian H, Gebrekidan MT, et al.
PloS one 2024; (19(4)):e0302017 doi:10.1371/journal.pone.0302017.
PMID: 38603731 - 2
[Cosmetic and functional results after resection of cutaneous neurofibroma in neurofibromatosis type 1 : Operation of neurofibroma improves quality of life while having moderate complications].
Walz B, Pfefferle V, Häfner HM, Kofler L
Dermatologie (Heidelberg, Germany) 2022; (74(12)):961-968 doi:10.1007/s00105-023-05220-8.
PMID: 37728798 - 3
Oral Plexiform Neurofibroma Involving the Buccal Mucosa: A Case Report.
Begum NF, Ramalingam K, Ramani P, M A
Cureus 2024; (16(9)):e70514 doi:10.7759/cureus.70514.
PMID: 39479119 - 4
Challenging Management of Plexiform Schwannoma and Plexiform Neurofibroma.
Nicoli TK, Saat R, Tarkkanen J, et al.
The Journal of craniofacial surgery 2022; (33(3)):803-808 doi:10.1097/SCS.0000000000008381.
PMID: 34855632 - 5
The impact of cutaneous neurofibromas on quality of life and mental health in neurofibromatosis type 1.
Dance B, Dardare A, Fleming J, et al.
The Journal of dermatology 2024; (51(8)):1050-1059 doi:10.1111/1346-8138.17276.
PMID: 38923593 - 6
Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.
Cannon A, Sarin KY, Petersen AK, et al.
Clinical trials (London, England) 2024; (21(1)):67-72 doi:10.1177/17407745231178839.
PMID: 37269078 - 7
Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib: A Nonrandomized Clinical Trial.
Gross AM, Reid OH, Baldwin LA, et al.
JAMA dermatology 2025; doi:10.1001/jamadermatol.2024.6574.
PMID: 40009403 - 8
Target Product Profile for Cutaneous Neurofibromas: Clinical Trials to Prevent, Arrest, or Regress Cutaneous Neurofibromas.
Ly I, Romo CG, Gottesman S, et al.
The Journal of investigative dermatology 2023; (143(8)):1388-1396 doi:10.1016/j.jid.2023.01.041.
PMID: 37294242 - 9
[Clinical experiences in precision treatment of giant plexiform neurofibromas of head, face, and neck].
Liu B, Hu Z
Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery 2024; (38(10)):1208-1213 doi:10.7507/1002-1892.202406085.
PMID: 39433494 - 10
Plexiform neurofibromatosis of the lower back: A rare case report.
Kc M, Sharma S, Shrestha JM
International journal of surgery case reports 2023; (111()):108812 doi:10.1016/j.ijscr.2023.108812.
PMID: 37716061 - 11
Peripheral nerve sheath tumors arising in salivary glands: A clinicopathologic study.
Guraya SS, Prayson RA
Annals of diagnostic pathology 2016; (23()):38-42.
PMID: 27402223 - 12
Isolated, Nonsyndromic Mucocutaneous Plexiform Neurofibromas: A Systematic Review of the Clinicopathologic Features.
Ho JD, Ho JAS, Ruddock R, Spencer SA
The American Journal of dermatopathology 2022; (44(12)):904-912 doi:10.1097/DAD.0000000000002322.
PMID: 36395447 - 13
Neurofibromatosis type 1-associated plexiform neurofibromas of the neck: topography of lesions and surgical treatment data of 69 patients.
Friedrich RE, Löhmann DM
Oral and maxillofacial surgery 2024; (28(1)):393-404 doi:10.1007/s10006-023-01155-5.
PMID: 37173460 - 14
FDA Approval Summary: Selumetinib for Plexiform Neurofibroma.
Casey D, Demko S, Sinha A, et al.
Clinical cancer research : an official journal of the American Association for Cancer Research 2021; (27(15)):4142-4146 doi:10.1158/1078-0432.CCR-20-5032.
PMID: 33712511 - 15
Selumetinib in Children with Inoperable Plexiform Neurofibromas.
Gross AM, Wolters PL, Dombi E, et al.
The New England journal of medicine 2020; (382(15)):1430-1442 doi:10.1056/NEJMoa1912735.
PMID: 32187457 - 16
Targeted Therapies in Neurofibromatosis Type 1.
Sato AA, Earl D, Wallace SE
American journal of medical genetics. Part C, Seminars in medical genetics 2025; (199(3)):154-160 doi:10.1002/ajmg.c.32151.
PMID: 40968507
This page provides educational information about neurofibroma treatment and regrowth risks. It does not replace professional medical advice from your dermatologist, neurosurgeon, or NF specialist.
Get notified when new evidence is published on Neurofibromatosis type 1.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.